PRO ("The Window Is Open"): In patients with cirrhosis with prior variceal hemorrhage and ascites, the clinical benefits of nonselective beta-blockers outweigh the risks and should be prescribed.
作者信息
Tholey Danielle, Roth Nitzan, Schiano Thomas
机构信息
Recanati/Miller Transplantation Institute, Division of Liver Diseases Mount Sinai Medical Center New York NY.
出版信息
Clin Liver Dis (Hoboken). 2018 Jun 5;11(5):119-122. doi: 10.1002/cld.700. eCollection 2018 May.
Abstract
摘要
相似文献
1
PRO ("The Window Is Open"): In patients with cirrhosis with prior variceal hemorrhage and ascites, the clinical benefits of nonselective beta-blockers outweigh the risks and should be prescribed.专业意见（“窗口已打开”）：在有既往静脉曲张出血和腹水的肝硬化患者中，非选择性β受体阻滞剂的临床益处大于风险，应予以处方。
Clin Liver Dis (Hoboken). 2018 Jun 5;11(5):119-122. doi: 10.1002/cld.700. eCollection 2018 May.
2
CON ("The window is closed"): In patients with cirrhosis with ascites, the clinical risks of nonselective beta-blocker outweigh the benefits and should NOT be prescribed.禁忌（“窗户关闭”）：在肝硬化腹水患者中，非选择性β受体阻滞剂的临床风险大于益处，不应开具此类药物。
Clin Liver Dis (Hoboken). 2018 Jun 5;11(5):123-127. doi: 10.1002/cld.699. eCollection 2018 May.
3
The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites.β受体阻滞剂对肝硬化、门静脉高压和腹水患者的有益作用。
Am J Med Sci. 2016 Feb;351(2):169-76. doi: 10.1016/j.amjms.2015.11.018.
4
Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.非选择性β受体阻滞剂对终末期肝硬化患者死亡率的影响。
Ann Pharmacother. 2020 Apr;54(4):322-330. doi: 10.1177/1060028019886529. Epub 2019 Nov 8.
5
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.非选择性β受体阻滞剂不会影响肝硬化腹水患者的死亡率：三项随机对照试验的事后分析，共纳入 1198 例患者。
Hepatology. 2016 Jun;63(6):1968-76. doi: 10.1002/hep.28352. Epub 2016 Jan 5.
6
NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: "THE THERAPEUTIC WINDOW".肝硬化患者使用非选择性β受体阻滞剂：“治疗窗”
Rev Med Chir Soc Med Nat Iasi. 2016 Jan-Mar;120(1):23-8.
7
Nonselective β-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis.非选择性β受体阻滞剂与肝硬化伴腹水患者生存：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2016 Aug;14(8):1096-1104.e9. doi: 10.1016/j.cgh.2016.01.012. Epub 2016 Jan 30.
8
Should children with esophageal varices receive beta-blockers for the primary prevention of variceal hemorrhage?患有食管静脉曲张的儿童是否应接受β受体阻滞剂以预防静脉曲张出血？
Can J Gastroenterol. 2005 Nov;19(11):661-6. doi: 10.1155/2005/935161.
9
Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers.
Gastroenterology. 2001 Oct;121(4):908-14.
10
[Prevention of esophageal variceal bleeding].[食管静脉曲张出血的预防]
Korean J Gastroenterol. 2010 Sep;56(3):155-67. doi: 10.4166/kjg.2010.56.3.155.
本文引用的文献
1
Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.预防复发性静脉曲张出血的风险分层：一项个体患者荟萃分析的结果
Hepatology. 2017 Oct;66(4):1219-1231. doi: 10.1002/hep.29267. Epub 2017 Aug 26.
2
Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.非选择性β受体阻滞剂治疗对肝硬化静脉曲张患者的肾功能无影响。
Scand J Gastroenterol. 2017 Sep;52(9):1008-1015. doi: 10.1080/00365521.2017.1329456. Epub 2017 May 22.
3
Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.非选择性β受体阻滞剂与肝硬化腹水患者的死亡率增加无关。
Liver Int. 2017 Sep;37(9):1334-1344. doi: 10.1111/liv.13409. Epub 2017 Mar 30.
4
Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.卡维地洛的使用与肝硬化和腹水患者的生存改善相关。
J Hepatol. 2017 Jul;67(1):40-46. doi: 10.1016/j.jhep.2017.02.005. Epub 2017 Feb 16.
5
Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.肝硬化门静脉高压出血：风险分层、诊断及管理：美国肝病研究协会2016年实践指南
Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1.
6
Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers.普萘洛尔对失代偿期肝硬化患者生存率的影响：一项基于丹麦全国患者登记系统的研究
Liver Int. 2016 Sep;36(9):1304-12. doi: 10.1111/liv.13119. Epub 2016 Apr 4.
7
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.非选择性β受体阻滞剂不会影响肝硬化腹水患者的死亡率：三项随机对照试验的事后分析，共纳入 1198 例患者。
Hepatology. 2016 Jun;63(6):1968-76. doi: 10.1002/hep.28352. Epub 2016 Jan 5.
8
Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.非选择性β受体阻滞剂治疗与降低慢加急性肝衰竭患者全身炎症反应严重程度和改善患者生存相关。
J Hepatol. 2016 Mar;64(3):574-82. doi: 10.1016/j.jhep.2015.10.018. Epub 2015 Oct 28.
9
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.门静脉高压领域共识的拓展：巴韦诺VI共识研讨会报告：门静脉高压风险分层与个体化治疗
J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.
10
Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation.非选择性β受体阻滞剂可改善等待肝移植患者腹水的生存率。
Gut. 2015 Jul;64(7):1111-9. doi: 10.1136/gutjnl-2013-306502. Epub 2014 Oct 3.
Zotero 插件